Berenberg Bank Issues Positive Forecast for AstraZeneca (LON:AZN) Stock Price

AstraZeneca (LON:AZN) had its price target increased by Berenberg Bank from £145 to £160 in a report published on Tuesday, MarketBeat reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently issued reports on AZN. Citigroup assumed coverage on shares of AstraZeneca in a research note on Tuesday. They issued a “buy” rating and a £170 price objective for the company. Deutsche Bank Aktiengesellschaft upped their target price on AstraZeneca from £105 to £110 and gave the company a “sell” rating in a research report on Thursday, January 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a £150 price target on shares of AstraZeneca in a research report on Monday, November 10th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research report on Thursday, January 15th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of £145.83.

AstraZeneca Stock Down 2.3%

Shares of LON:AZN traded down GBX 324 during trading on Tuesday, hitting £135.56. 28,814,969 shares of the company were exchanged, compared to its average volume of 69,479,617. The firm’s 50 day moving average price is £137.69 and its 200-day moving average price is £125.53. AstraZeneca has a 12-month low of GBX 9,573.51 and a 12-month high of £144.10. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The stock has a market capitalization of £210.16 billion, a P/E ratio of 22.52, a PEG ratio of 0.86 and a beta of 0.17.

Insider Buying and Selling

In other AstraZeneca news, insider Nazneen Rahman sold 297 shares of AstraZeneca stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of £134.96, for a total value of £40,083.12. 0.14% of the stock is currently owned by insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.